Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 17 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

41%

7 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

8 recruiting

Enrollment Performance

Analytics

Phase 4
6(46.2%)
N/A
5(38.5%)
Phase 3
1(7.7%)
Phase 2
1(7.7%)
13Total
Phase 4(6)
N/A(5)
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT07570680Recruiting

Hemorrhage Stroke Decision Making Model Based Deep Learning (BrainHemoAI System)

Role: collaborator

NCT06284642Phase 4Recruiting

Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)

Role: collaborator

NCT07209787Phase 4Recruiting

SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak

Role: collaborator

NCT07302009Not ApplicableNot Yet Recruiting

Targeted Temperature Management Via Bladder Monitoring in ICH

Role: collaborator

NCT07296575Active Not Recruiting

Ultrasound Large-scale Model in Thyroid Field: A Multi-center Study on Medical-Engineering Integration

Role: collaborator

NCT07290699Phase 4Not Yet Recruiting

Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period

Role: collaborator

NCT04555226Not ApplicableRecruiting

The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)

Role: collaborator

NCT04974151Phase 4Recruiting

China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype

Role: collaborator

NCT04974138Phase 4Recruiting

China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)

Role: collaborator

NCT06810791Phase 3Recruiting

HVA vs IA/DA or VA in the Treatment of ND HR-AML

Role: collaborator

NCT06078839Phase 4Not Yet Recruiting

Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy

Role: collaborator

NCT05453721Not ApplicableRecruiting

Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Method in Identification of Intersegmental Plane(IMPLANE-0529)

Role: collaborator

NCT02636231Phase 2Unknown

Endostar for Locally Recurrent Nasopharyngeal Carcinoma

Role: collaborator

NCT02635048Not ApplicableCompleted

Mini-PCNL Versus Standard-PCNL For The Management of 20-40 mm Size Kidney Stones

Role: collaborator

NCT03620955Unknown

Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML

Role: collaborator

NCT03733834Unknown

SD vs. NSD Therapy in Elderly AML

Role: collaborator

NCT02398110Not ApplicableUnknown

Transvaginal NOTES Nephrectomy Versus Conventional Laparoscopic Nephrectomy

Role: lead

All 17 trials loaded